Molecular docking of aromatase inhibitors

Molecules

Volumn 16, Issue 5, 2011, Pages 3597-3617

  Suvannang, Naravut ^a   Nantasenamat, Chanin ^a   Isarankura Na Ayudhya, Chartchalerm ^a   Prachayasittikul, Virapong ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Aromatase; Aromatase inhibitors; Drug design; Molecular docking

Indexed keywords

EID: 79957614697     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules16053597     Document Type: Article

References (70)

1. Fontham, E.T.H.; Thun, M.J.; Ward, E.; Balch, A.J.; Delancey, J.O.L.; Samet, J.M. American Cancer Society perspectives on environmental factors and cancer. CA Cancer J. Clin. 2009, 59, 343-351.
2. Nelson, L.R.; Bulun, S.E. Estrogen production and action. J. Am. Acad. Dermatol. 2001, 45 (Suppl.), S116-S124. (Pubitemid 32783340)
3. Russo, J.; Lareef, M.H.; Balogh, G.; Guo, S.; Russo, I.H. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J. Steroid. Biochem. Mol. Biol. 2003, 87, 1-25. (Pubitemid 37421335)
4. Eisen, A.; Trudeau, M.; Shelley, W.; Messersmith, H.; Pritchard, K.I. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review. Cancer Treat. Rev. 2008, 34, 157-174.
5. Santen, R.J.; Santner, S.; Davis, B. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J. Clin. Endocrinol. Metab. 1978, 47, 1257-1265. (Pubitemid 9091287)
6. Graves, P.E.; Salhanick, H.A. Stereoselective inhibition of aromatase by enantiomers of aminoglutethimide. Endocrinology 1979, 105, 52-57. (Pubitemid 9199122)
7. Santen, R.J.; Misbin, R.I. Aminoglutethimide: Review of pharmacology and clinical use. Pharmacotherapy 1981, 1, 95-120. (Pubitemid 12016086)
8. Santen, R.J.; Worgul, T.J.; Lipton, A. Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma. Ann. Intern. Med. 1982, 96, 94-101. (Pubitemid 12205528)
9. Hughes, S.W.; Burley, D.M. Aminoglutethimide: a "side-effect" turned to therapeutic advantage. Postgrad. Med. J. 1970, 46, 409-416.
10. Demers, L.M.; Boucher, A.E.; Santen, R.J. Aminoglutethimide therapy in breast cancer: Relationship of blood levels to drug-related side effects. Clin. Physiol. Biochem. 1987, 5, 287-291. (Pubitemid 17137383)
11. Santen, R.J.; Samojlik, E.; Wells, S.A. Resistance of the ovary to blockade of aromatization with aminoglutethimide. J. Clin. Endocrinol. Metab. 1980, 51, 473-477. (Pubitemid 10022826)
12. Beretta, K.R.; Hoeffken, K.; Kvinnsland, S.; Trunet, P.; Chaudri, H.A.; Bhatnagar, A.S.; Goldhirsch, A.; Cavalli, F. CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer - A phase I study. Ann. Oncol. 1990, 1, 421-426. (Pubitemid 20356790)
13. Brueggemeier, R.W.; Hackett, J.C.; Diaz-Cruz, E.S. Aromatase inhibitors in the treatment of breast cancer. Endocrinol. Rev. 2005, 26, 331-345. (Pubitemid 40686647)
14. Cunningham, D.; Powles, T.J.; Dowsett, M.; Hutchison, G.; Brodie, A.M.H.; Ford, H.T.; Gazet, J.C.; Coombes, R.C. Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer. Cancer Chemother. Pharm. 1987, 20, 253-255. (Pubitemid 17163405)
15. Plourde, P.V.; Dyroff, M.; Dowsett, M.; Demers, L.; Yates, R.; Webster, A. ARIMIDEXTM: A new oral, once-a-day aromatase inhibitor. J. Steroid Biochem. Mol. Biol. 1995, 53, 175-179.
16. Dutta, U.; Pant, K. Aromatase inhibitors: Past, present and future in breast cancer therapy. Med. Oncol. 2008, 25, 113-124.
17. Gueto, C.; Torres, J.; Vivas-Reyes, R. CoMFA, LeapFrog and blind docking studies on sulfonanilide derivatives acting as selective aromatase expression regulators. Eur. J. Med. Chem. 2009, 44, 3445-3451.
18. Thurlimann, B.; Hess, D.; Koberle, D.; Senn, I.; Ballabeni, P.; Pagani, O.; Perey, L.; Aebi, S.; Rochlitz, C.; Goldhirsch, A. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95-a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res. Treat. 2004, 85, 247-254. (Pubitemid 38987259)
19. Akhtar, M.; Njar, V.C.O.; Wright, J.N. Mechanistic studies on aromatase and related C-C bond cleaving P-450 enzymes. J. Steroid Biochem. 1993, 44, 375-387. (Pubitemid 23126608)
20. Ghosh, D.; Griswold, J.; Erman, M.; Pangborn, W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 2009, 457, 219-223.
21. Wang, X.; Chen, S. Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor. Cancer Res. 2006, 66, 10281-10286. (Pubitemid 44799745)
22. Karkola, S.; Wahala, K. The binding of lignans, flavonoids and coumestrol to CYP450 aromatase: a molecular modelling study. Mol. Cell Endocrinol. 2009, 301, 235-244.
23. Loge, C.; Le Borgne, M.; Marchand, P.; Robert, J.M.; Le Baut, G.; Palzer, M.; Hartmann, R.W. Three-dimensional model of cytochrome P450 human aromatase. J. Enzyme. Inhib. Med. Chem. 2005, 20, 581-585. (Pubitemid 43994756)
24. Paoletta, S.; Steventon, G.B.; Wildeboer, D.; Ehrman, T.M.; Hylands, P.J.; Barlow, D.J. Screening of herbal constituents for aromatase inhibitory activity. Bioorg. Med. Chem. 2008, 16, 8466-8470.
25. Nagar, S.; Islam, M.A.; Das, S.; Mukherjee, A.; Saha, A. Pharmacophore mapping of flavone derivatives for aromatase inhibition. Mol. Divers. 2008, 12, 65-76.
26. Ariazi, E.A.; Leitão, A.; Oprea, T.I.; Chen, B.; Louis, T.; Bertucci, A.M.; Sharma, C.G. N.; Gill, S.D.; Kim, H.R.; Shupp, H.A.; Pyle, J.R.; Madrack, A.; Donato, A.L.; Cheng, D.; Paige, J.R.; Jordan, V.C. Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Mol. Cancer Ther. 2007, 6, 2817-2827. (Pubitemid 350206762)
27. Nantasenamat, C.; Naenna, T.; Isarankura Na-Ayudhya, C.; Prachayasittikul, V. Quantitative prediction of imprinting factor of molecularly imprinted polymers by artificial neural network. J. Comput. Aid. Mol. Des. 2005, 19, 509-524. (Pubitemid 43150057)
28. Piacham, T.; Isarankura-Na-Ayudhya, C.; Nantasenamat, C.; Yainoy, S.; Ye, L.; Bülow, L.; Prachayasittikul, V. Metalloantibiotic Mn(II)-bacitracin complex mimicking manganese superoxide dismutase. Biochem. Biophys. Res. Commun. 2006, 341, 925-930. (Pubitemid 43221754)
29. Prachayasittikul, V.; Isarankura-Na-Ayudhya, C.; Tantimongcolwat, T.; Nantasenamat, C.; Galla, H.J. EDTA-induced membrane fluidization and destabilization: Biophysical studies on artificial lipid membranes. Acta. Biochim. Biophys. Sin. 2007, 39, 901-913. (Pubitemid 350136898)
30. Nantasenamat, C.; Isarankura-Na-Ayudhya, C.; Naenna, T.; Prachayasittikul, V. Quantitative structure-imprinting factor relationship of molecularly imprinted polymers. Biosens. Bioelectron. 2007, 22, 3309-3317. (Pubitemid 46754891)
31. Nantasenamat, C.; Isarankura-Na-Ayudhya, C.; Tansila, N.; Naenna, T.; Prachayasittikul, V. Prediction of GFP spectral properties using artificial neural network. J. Comput. Chem. 2007, 28, 1275-1289. (Pubitemid 46653001)
32. Suksrichavalit, T.; Prachayasittikul, S.; Piacham, T.; Isarankura-Na-Ayudhya, C.; Nantasenamat, C.; Prachayasittikul, V. Copper complexes of nicotinic-aromatic carboxylic acids as superoxide dismutase mimetics. Molecules 2008, 13, 3040-3056.
33. Isarankura-Na-Ayudhya, C.; Nantasenamat, C.; Buraparuangsang, P.; Piacham, T.; Ye, L.; Bülow, L.; Prachayasittikul, V. Computational insights on sulfonamide imprinted polymers. Molecules 2008, 13, 3077-3091.
34. Nantasenamat, C.; Isarankura-Na-Ayudhya, C.; Naenna, T.; Prachayasittikul, V. Prediction of bond dissociation enthalpy of antioxidant phenols by support vector machine. J. Mol. Graph. Model. 2008, 27, 188-196.
35. Nantasenamat, C.; Piacham, T.; Tantimongcolwat, T.; Naenna, T.; Isarankura-Na-Ayudhya, C.; Prachayasittikul, V. QSAR model of the quorum-quenching N-acyl-homoserine lactone lactonase activity. J. Biol. Syst. 2008, 16, 279-293. (Pubitemid 351799306)
36. Nantasenamat, C.; Isarankura-Na-Ayudhya, C.; Naenna, T.; Prachayasittikul, V. A practical overview of quantitative structure-activity relationship. EXCLI J. 2009, 74-88.
37. Suksrichavalit, T.; Prachayasittikul, S.; Nantasenamat, C.; Isarankura-Na-Ayudhya, C.; Prachayasittikul, V. Copper complexes of pyridine derivatives with superoxide scavenging and antimicrobial activities. Eur. J. Med. Chem. 2009, 44, 3259-3265.
38. Piacham, T.; Nantasenamat, C.; Suksrichavalit, T.; Puttipanyalears, C.; Pissawong, T.; Maneewas, S.; Isarankura-Na-Ayudhya, C.; Prachayasittikul, V. Synthesis and theoretical study of molecularly imprinted nanospheres for recognition of tocopherols. Molecules 2009, 14, 2985-3002.
39. Thippakorn, C.; Suksrichavalit, T.; Nantasenamat, C.; Tantimongcolwat, T.; Isarankura-Na-Ayudhya, C.; Naenna, T.; Prachayasittikul, V. Modeling the LPS neutralization activity of anti-endotoxins. Molecules 2009, 14, 1869-1888.
40. Worachartcheewan, A.; Nantasenamat, C.; Naenna, T.; Isarankura-Na- Ayudhya, C.; Prachayasittikul, V. Modeling the activity of furin inhibitors using artificial neural network. Eur. J. Chem. 2009, 44, 1664-1673.
41. Prachayasittikul, S.; Wongsawatkul, O.; Worachartcheewan, A.; Nantasenamat, C.; Ruchirawat, S.; Prachayasittikul, V. Elucidating the Structure-Activity relationships of the vasorelaxation and antioxidation properties of thionicotinic acid derivatives. Molecules 2010, 15, 198-214.
42. Diller, D.J.; Li, R. Kinases, Homology Models, and High Throughput Docking. J. Med. Chem. 2003, 46, 4638-4647. (Pubitemid 37271613)
43. Roy, P.P.; Roy, K. Docking and 3D-QSAR studies of diverse classes of human aromatase (CYP19) inhibitors. J. Mol. Model. 2010, 1597-1616.
44. Laskowski, R.A.; Hutchinson, E.G.; Michie, A.D.; Wallace, A.C.; Jones, M.L.; Thornton, J.M. PDBsum: A Web-based database of summaries and analyses of all PDB structures. Trends. Biochem. Sci. 1997, 22, 488-490. (Pubitemid 27515917)
45. Ni, C.Z.; Li, C.; Wu, J.C.; Spada, A.P.; Ely, K.R. Conformational restrictions in the active site of unliganded human caspase-3. J. Mol. Recognit. 2003, 16, 121-124. (Pubitemid 36815050)
46. Becker, J.W.; Rotonda, J.; Soisson, S.M.; Aspiotis, R.; Bayly, C.; Francoeur, S.; Gallant, M.; Garcia-Calvo, M.; Giroux, A.; Grimm, E.; Han, Y.; McKay, D.; Nicholson, D.W.; Peterson, E.; Renaud, J.; Roy, S.; Thornberry, N.; Zamboni, R. Reducing the Peptidyl Features of Caspase-3 Inhibitors: A Structural Analysis. J. Med. Chem. 2004, 47, 2466-2474. (Pubitemid 38580085)
47. De Graaf, C.; Oostenbrink, C.; Keizers, P.H.J.; Van Der Wijst, T.; Jongejan, A.; Vermeulen, N.P.E. Catalytic site prediction and virtual screening of cytochrome P450 2D6 substrates by consideration of water and rescoring in automated docking. J. Med. Chem. 2006, 49, 2417-2430.
48. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19, 1639-1662. (Pubitemid 128590223)
49. Hong, Y.; Cho, M.; Yuan, Y.C.; Chen, S. Molecular basis for the interaction of four different classes of substrates and inhibitors with human aromatase. Biochem. Pharmacol. 2008, 75, 1161-1169.
50. Hong, Y.; Li, H.; Yuan, Y.-C.; Chen, S. Molecular Characterization of Aromatase. Ann. NY. Acad. Sci. 2009, 1155, 112-120.
51. Goss, P.E.; Strasser, K. Aromatase inhibitors in the treatment and prevention of breast cancer. J. Clin. Oncol. 2001, 19, 881-894. (Pubitemid 32119104)
52. Geisler, J.; Lønning, P.E. Endocrine effects of aromatase inhibitors and inactivators in vivo: Review of data and method limitations. J. Steroid Biochem Mol. Biol. 2005, 95, 75-81. (Pubitemid 41148977)
53. Feuillan, P.P.; Jones, J.; Cutler, G.B., Jr. Long term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome. J. Clin. Endocrinol. Metab. 1993, 77, 647-651. (Pubitemid 23298642)
54. Wheeler, S.E.; Houk, K.N. Substituent effects in the benzene dimer are due to direct interactions of the substituents with the unsubstituted benzene. J. Am. Chem. Soc. 2008, 130, 10854-10855.
55. Favia, A.D.; Cavalli, A.; Masetti, M.; Carotti, A.; Recanatini, M. Three-dimensional model of the human aromatase enzyme and density functional parameterization of the iron-containing protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes. Proteins: Structure Function Genetics 2006, 62, 1074-1087. (Pubitemid 43364170)
56. Neves, M.A.C.; Dinis, T.C.P.; Colombo, G.; Sáe Melo, M.L. Fast three dimensional pharmacophore virtual screening of new potent Non-steroid aromatase inhibitors. J. Med. Chem. 2009, 52, 143-150.
57. Buzdar, A.U.; Robertson, J.F.; Eiermann, W.; Nabholtz, J.M. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002, 95, 2006-2016. (Pubitemid 35222182)
58. Wolf, L.K. PyRx. C&EN 2009, 87, 31.
59. Favia, A.D.; Cavalli, A.; Masetti, M.; Carotti, A.; Recanatini, M. Three-dimensional model of the human aromatase enzyme and density functional parameterization of the iron-containing protoporphyrin IX for a molecular dynamics study of heme-cysteinato cytochromes. Proteins 2006, 62, 1074-1087. (Pubitemid 43364170)
60. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman, J.R.; Montgomery, J. A., Jr.; Vreven, T.; Kudin, K.N.; Burant, J.C.; Millam, J.M.; Iyengar, S.S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G.A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J.E.; Hratchian, H.P.; Cross, J.B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R.E.; Yazyev, O.; Austin, A.J.; Cammi, R.; Pomelli, C.; Ochterski, J.W.; Ayala, P.Y.; Morokuma, K.; Voth, G.A.; Salvador, P.; Dannenberg, J.J.; Zakrzewski, V.G.; Dapprich, S.; Daniels, A.D.; Strain, M.C.; Farkas, O.; Malick, D.K.; Rabuck, A.D.; Raghavachari, K.; Foresman, J.B.; Ortiz, J.V.; Cui, Q.; Baboul, A.G.; Clifford, S.; Cioslowski, J.; Stefanov, B.B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R.L.; Fox, D.J.; Keith, T.; Al-Laham, M.A.; Peng, C.Y.; Nanayakkara, A.; Challacombe, M.; Gill, P.M.W.; Johnson, B.; Chen, W.; Wong, M.W.; Gonzalez, C.; Pople, J.A. Gaussian 03; Gaussian, Inc., Wallingford, CT, USA, 2003.
61. Becke, A.D. Density-functional thermochemistry. III. The role of exact exchange. J. Chem. Phys. 1993, 98, 5648-5652.
62. Krieger, E.; Nabuurs, S.B.; Vriend, G. Homology modeling. Meth. Biochem. Anal. 2003, 44, 509-523.
63. Krieger, E.; Koraimann, G.; Vriend, G. Increasing the precision of comparative models with YASARA NOVA - A self-parameterizing force field. Protein. Struct. Funct. Genet. 2002, 47, 393-402. (Pubitemid 34438688)
64. Cornell, W.D.; Cieplak, P.; Bayly, C.I.; Gould, I.R.; Merz, K.M., Jr.; Ferguson, D.M.; Spellmeyer, D.C.; Fox, T.; Caldwell, J.W.; Kollman, P.A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
65. Krieger, E.; Nielsen, J.E.; Spronk, C.A.E.M.; Vriend, G. Fast empirical pKa prediction by Ewald summation. J. Mol. Model. 2006, 25, 481-486. (Pubitemid 44667584)
66. Essmann, U.; Perera, L.; Berkowitz, M.L.; Darden, T.; Lee, H.; Pedersen, L.G. A smooth particle mesh Ewald method. J. Chem. Phys. 1995, 103, 8577-8593.
67. Solis, F.J.; Wets, R.J.B. Minimization by random search techniques. Math. Oper. Res. 1981, 6, 19-30.
68. Morris, G.M.; Huey, R.; Olson, A.J. Using AutoDock for ligand-receptor docking. Curr. Prot. Bioinf. 2008, 24, 8.14.1-8.14.40.
69. Sousa, S.F.; Fernandes, P.A.; Ramos, M.J. Protein-ligand docking: Current status and future challenges. Proteins 2006, 65, 15-26. (Pubitemid 44320611)
70. Cheng, T.; Zhao, Y.; Li, X.; Lin, F.; Xu, Y.; Zhang, X.; Li, Y.; Wang, R.; Lai, L. Computation of octanol-water partition coefficients by guiding an additive model with knowledge. J. Chem. Inf. Model. 2007, 47, 2140-2148. (Pubitemid 350275080)